Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / M•••••••

M••••••• Announces $400 million Strategic Investment by O••••••• Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

Growth investmentannouncedannounced Jul 7, 2026Fact
What happened
Target
M•••••••
Platform
not an add-on on record
Control
unknown
Share acquired
unknown
Industry
healthcare / clinic
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
3 named
Buy side
  • M•••••• B••••Deal partnerconfirmed
    “M•••••• B••••, Partner at O••••••• Capital, added, “M••••••• is in the rare position of having three potentially approvable therapies within the next 12 to 24 months, two of which have significant commercial potential.”
  • O••••••• C•••••• M••••••••• L••Sponsorconfirmed
    “O••••••• Capital is a private investment firm formed in 2013 with assets under management in excess of $3.5 billion, focused exclusively on investing in the global healthcare industry and specializing in flexible investment structures customized to meet the specific needs of its transaction partners”
Side not stated
  • M•••••••Targetconfirmed
    “M••••••• Announces $400 million Strategic Investment by O••••••• Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)”
Evidence
“M••••••• Announces $400 million Strategic Investment by O••••••• Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026
M••••••• Announces $400 million Strategic Investment by O••••••• Capital to Support Develo | Private Equity Intelligence | DFX